Skip to main content

ETHNOS_APP

Home • Search • Journals • List 0

Substandard and falsified antibiotics

Neglected drivers of antimicrobial resistance

Bibliographic Data

ID21879175
AuthorsGuillermo A Zabala (0000-0001-8382-7748, Mahosot Hospital), Khonsavath Bellingham (0000-0001-6162-2098, Mahosot Hospital), Vayouly Vidhamaly (0000-0003-1941-8944, Mahosot Hospital), Phonepasith Boupha (0000-0002-2094-7512, Mahosot Hospital), Kem Boutsamay (0000-0001-8152-0523, Mahosot Hospital), Paul N Newton (0000-0002-4608-6431, Mahosot Hospital), Céline Caillet (0000-0002-5554-2603, Mahosot Hospital, corresponding author)
Year2022
Volume7
Issue8
Pagese008587
Publication date2022-08-01
Peer ReviewedYes
Open AccessYes
TypeARTICLE
VenueBMJ Global Health (JOURNAL)
Journal identifiersISSN: 2059-7908 • E-ISSN: 2059-7908
PublisherBMJ (PUBLISHER • GB)
DOI10.1136/bmjgh-2022-008587
PMID35981806
OpenAlexW4292212781
LanguageEN
Citations received12
References cited40

OBJECTIVES: Antimicrobial resistance (AMR) is a significant global health threat with substandard and falsified (SF) antibiotics being neglected contributing factors. With their relationships poorly understood, more research is needed in order to determine how interventions to reduce SF antibiotics should be ranked as priorities in national AMR action plans. We assessed the evidence available on the global prevalence of SF antibiotics, examined the quality of the evidence and discussed public health impact. MATERIALS/METHODS: We searched PubMed, Embase, Google and Google Scholar for publications on antibiotic quality up to 31 December 2020. Publications reporting on the prevalence of SF antibiotics were evaluated for quantitative analysis and assessed using the Medicines Quality Assessment Reporting Guidelines. RESULTS: Of the 10 137 screened publications, 648 were relevant to antibiotic quality. One hundred and six (16.4%) surveys, published between 1992 and 2020 and conducted mainly in low-income and middle-income countries (LMICs) (89.9% (480/534) of the data points), qualified for quantitative analysis. The total number of samples tested for quality in prevalence surveys was 13 555, with a median (Q1-Q3) number of samples per survey of 47 (21-135). Of the 13 555 samples, 2357 (17.4%) failed at least one quality test and the median failure frequency (FF) per survey was 19.6% (7.6%-35.0%). Amoxicillin, sulfamethoxazole-trimethoprim and ciprofloxacin were the most surveyed antibiotics, with FF of 16.1% (355/2208), 26.2% (329/1255) and 10.4% (366/3511), respectively. We identified no SF survey data for antibiotics in the WHO 'Reserve' group. The mean Medicine Quality Assessment Reporting Guidelines score was 11 (95% CI 10.1 to 12.2) out of 26. CONCLUSIONS: SF antibiotics are widely spread with higher prevalence in LMICs. The quality of the evidence is poor, and these data are not generalisable that 17.4% of global antibiotic supply is SF. However, the evidence we have suggests that interventions to enhance regulatory, purchasing and financial mechanisms to improve the global antibiotic supply are needed. PROSPERO REGISTRATION NUMBER: CRD42019124988

Antibiotic resistance · Antibiotics · Antimicrobial · Biology · Environmental health · Intensive care medicine · Antibiotic Use and Resistance · Medicine · Pharmaceutical Economics and Policy · Pharmaceutical Quality and Counterfeiting · Microbiology

  • Self-medication under uncertainty

    Open Access•Renate Hartwig, Moumouni Koala et al.•Journal of Development Economics•2027

  • Why Assuring the Quality of Antimicrobials Is a Global Imperative

    Open Access•Amy B Cadwallader, Kavitha Nallathambi et al.•The AMA Journal of Ethic•2024

  • Knowledge and Practices on Household Disposal of Unused Antimicrobials in Ho Municipality, Ghana

    Open Access•Thelma Mpoku Alalbila, Jonathan Jato et al.•International Journal of…•2025

  • The quality of antiretroviral medicines

    Open Access•Ngan Thi Do, Phonepasith Boupha et al.•BMJ Global Health•2023

  • Substandard and falsified antibiotics are associated with antimicrobial resistance

    Open Access•Elisa M Maffioli, Yun-Chieh Lu et al.•BMJ Global Health•2025

  • Estimating the prevalence of poor-quality anti-TB medicines

    Open Access•Patricia Tabernero, Paul N Newton•BMJ Global Health•2023

  • Shaping the future of global access to safe, effective, appropriate and quality health products

    Open Access•Raffaella Ravinetto, RODRIGO HENRÍQUEZ et al.•BMJ Global Health•2024

  • ‘Prevalence, experience and awareness of substandard and falsified medicines among the public and healthcare professionals in Jordan’

    Open Access•Maysa M Falah, Eman Daar et al.•BMJ Global Health•2025

  • A randomised survey of the quality of antibiotics and other essential medicines in Indonesia, with volume-adjusted estimates of the prevalence of substandard medicines

    Open Access•Elizabeth Pisani, Ayu Rahmawati et al.•PLOS Global Public Health•2024

  • Tiered manufacturing of pharmaceuticals as a commercial determinant of health

    Open Access•Jean Christophe Rusatira, Eishita Pal et al.•PLOS Global Public Health•2026

  • Excessive active pharmaceutical ingredients in substandard and falsified drugs should also raise concerns in low-income countries

    Open Access•Elisa M Maffioli, Marie C Montás et al.•Journal of Global Health•2024

  • Medicines in motion

    Open Access•K Hampshire, Heather Hamill et al.•Social Science & Medicine•2025

  • Global increase and geographic convergence in antibiotic consumption between 2000 and 2015

    Open Access•Eili Klein, Thomas P Van Boeckel et al.•Proceedings of the National…•2018

  • Understanding the mechanisms and drivers of antimicrobial resistance

    Open Access•Alison H Holmes, Luke Moore et al.•The Lancet•2016

  • Global, regional, and national sepsis incidence and mortality, 1990–2017

    Open Access•Kristina E Rudd, Sarah C Johnson et al.•The Lancet•2020

  • A systematic review of substandard, falsified, unlicensed and unregistered medicine sampling studies

    Open Access•Dominic McManus, Bernard D Naughton•BMJ Global Health•2020

Unique citing works12
Citations per year4
Citation span2023 - 2027 (5)
Citation velocityrecent
Highly citedNo
Citation typesNeutral: 9

Tools

Open DOIOpen Access
Ethnos_APP • Open Source Project • MIT License • Frontend v2.0.0 • Privacy and Cookies • API Documentation: api.ethnos.app/docs • API Source Code: GitHub • DOI: 10.5281/zenodo.17049435 • Frontend Source Code: GitHub • DOI: 10.5281/zenodo.17050053 • cruz.rio.br • Expectantes Misericordiae